Researchers have demonstrated that artificial intelligence can provide a predictive score for the efficacy of immunotherapy in cancer patients.
Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice
Find out more about the utility of clinical characteristics in the selection of patients with advanced NSCLC as potential candidates for single-agent anti-PD-1/PD-L1 immunotherapy in this open access Future Oncology review article.
Find out the key features of the breast tumor microenvironment as well as putative predictive biomarkers established in other tumor types. Insights from both fields could guide future studies to enable personalized breast cancer immunotherapy.
Delve deeper into the promising PD-L1 research being published, in this patient perspective piece from Stage IV melanoma patient T.J. Sharpe.
This review summarizes the past decade of immunotherapy for non-small-cell lung cancer, gives an updated overview of trials in this field, and the context of future development in this exciting field.
In this interview with James Gulley find out about Phase I clinical trial for M7824 (a bifunctional fusion protein immunotherapy that targets both PD-L1 and TGF-beta), which has demonstrated preliminary effectiveness in patients with advanced solid tumors.
Could you give us a brief overview of the SCORES trial? The SCORES trial was…
A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometry
Discover preliminary data for a new assay workflow to detect the presence of PD-L1 and PD-L2 on the surface of tumor cells that have broken away from the tumor and entered the blood in this research article from Future Science OA.
PROGRAM OVERVIEW This case-based enduring activity will cover the treatment and management of patients with…